The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group’s investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the ...
A new medical technology expected to be on the market in 2027 is poised to help patients in middle America have greater access to heart transplants. Xvivo Perfusion, a leader in organ transplant ...
Our submission on the post implementation review of Medicare funded cardiac imaging items (second consultation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results